Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis

Exclusion Criteria

• •Evidence of OA in the contralateral knee with a Kellgren-Lawrence score greater than 2
• •If a woman of child-bearing potential, the study participant must not be pregnant or attempt to become pregnant while actively taking part in the study.
• •Steroid injection in either knee within 60 days of providing informed consent
• •The subject must not be diagnosed with any of the following diseases at the time of consent:
• •* Osteonecrosis
• •* Active autoimmune disease
• •* Serious cardiac condition
• •* Psychotic Diseases
• •* Epilepsy
• •* Uncontrolled diabetes
• •Prescribed immunosuppressive therapy at the time of consent
• •Evidence of cancer at the time of consent
• •History of alcohol or substance abuse
• •Regular smoker at the time of consent
• •Received experimental medication or participated in another clinical study within 60 days of providing informed consent
• •Concurrent diseases or circumstances that the Investigator judges to be a potential risk to patient health or a confounding variable in the assessment of study endpoints.